Skip to main content
Premium Trial:

Request an Annual Quote

... As Firm Secures Rights to RNAture s Nucleic Acid Purification Products from Hitachi

NEW YORK, May 3 (GenomeWeb News) - Qiagen said today that it has acquired the worldwide exclusive rights and licenses to manufacture and market all of RNAture's nucleic acid isolation products from its parent company, HitachiChemicalResearchCenter.

 

Pursuant to the companies' agreement, Hitachi Chemical Research will transfer all current commercial operations to Qiagen. Additional terms were not disclosed. Qiagen said it does not expect the transaction to have a material impact on its financial outlook for 2005.

 

According to Qiagen, RNAture's product portfolio focuses on mRNA isolation products and comprises solutions for the capture of cellular poly(A)+ RNA in the wells of specially treated microplates, and includes products marketed under the GenePlate name.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.